THERAPY DOSSIER · th-2aac18611232

Subtype-selective phosphodiesterase 4B (PDE4B) inhibitor

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27383587 ↗2016Reported benefit

Chronic Cognitive Dysfunction after Traumatic Brain Injury Is Improved with a Phosphodiesterase 4B Inhibitor.

RatTBIFluid percussionSprague-DawleyMaleAdministered at 3 months after surgery, before each behavioural task

Model: Moderate parasagittal fluid percussion traumatic brain injury

The selective PDE4B inhibitor significantly reversed injury-induced deficits in cue and contextual fear conditioning and water maze retention, reduced the deficit in basal synaptic transmission, rescued long-term potentiation expression, lowered TNF-alpha and increased phosphorylated CREB after inj…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…